Cardinal Health stock holds in mid-$220s as fresh earnings beat and guidance support valuation

Cardinal Health Inc. (US14149Y1082) stock is trading in the mid-$220s in late August 2026, only a modest distance below its 12-month peak of $258.30 after a strong earnings beat and higher guidance reported on August 11, 2026. Per a recent performance overview dated August 23, 2026, the shares last closed at $229.48, leaving investors with a price that sits well above the 12-month low of $145.87 but still below the recent high watermark of $258.30.

Fresh quarterly earnings beat consensus by a wide margin

In the most recently reported quarter, which the company presented on August 11, 2026, Cardinal Health delivered adjusted earnings per share of $2.91, clearly ahead of the consensus estimate of $2.42 that financial data providers had compiled for the period. The $0.49 EPS gap represents earnings that were roughly 20.2 percent above expectations and underscores how the business has been converting revenue into profit more effectively than analysts had anticipated. According to an earnings-focused article published on August 23, 2026, quarterly revenue came in at $63.67 billion for the latest reported period, versus an expectation of $65.15 billion that had been embedded in the same consensus dataset, so the company slightly underperformed the top-line forecast even as it substantially outperformed on the bottom line. This detailed analysis of the quarter notes that the earnings beat has been the main driver of recent share-price resilience.

The earnings quality discussion in that overview highlights how the latest quarter benefited from a one-time refund on emergency-powers tariffs within the Global Medical Products and Distribution segment. A separate coverage of segment dynamics describes how those tariffs and their subsequent refund influenced reported profit, indicating that the refund lifted fourth-quarter EPS by $0.31 out of the total $2.91 reported, contributing roughly 15 percentage points to the 40 percent year-over-year EPS growth rate for the quarter. This segment-focused article emphasizes that while such one-time items help the current quarter, management still faces ongoing work to structurally improve the medical segment.

Looking beyond a single quarter, a separate performance summary shows that for fiscal 2026 Cardinal Health generated revenue of $254.2 billion, representing 14 percent growth compared with the previous fiscal year, and achieved a 10 percent increase in net earnings to $1.7 billion. That same summary links this fundamental expansion to a stock price of $258.30 at one point, underscoring that the equity market has been willing to recognize the company’s multi-year growth trajectory when fundamentals and guidance line up convincingly. An in-depth analysis of an executive stock transaction uses these full-year figures to illustrate how the company’s improving earnings base has supported capital gains for shareholders.

Guidance for fiscal 2027 and valuation context

The same August 23, 2026 earnings commentary indicates that Cardinal Health has issued guidance for fiscal 2027 adjusted EPS in a range of $12.40 to $12.60. At the latest referenced share price of $229.48, the midpoint of this guidance implies a forward price-to-earnings ratio around 18.2, suggesting that the market is pricing the stock at a premium that reflects both defensive healthcare characteristics and the company’s recent ability to surpass profit expectations. The guidance band itself sits clearly above the trailing 12-month adjusted EPS run rate derived from recent quarters, which sends a signal that management expects further profit scaling as its segments stabilize and volume growth continues.

The same analysis notes that Cardinal Health shares currently carry an aggregated recommendation of “Moderate Buy” from the analyst community, with a consensus target price of $266.56. With the last closing quote at $229.48, the consensus target implies roughly 16.2 percent upside from the latest market level, which is notable in the context of a stock that already trades more than 57 percent above its 12-month low of $145.87. Institutional-position coverage with embedded analyst data refers to this same target range and rating, reinforcing the picture of a company that sits in the middle of an earnings-led rerating cycle rather than at the start or end.

An additional institutional-investor alert shows that a quantitative investment firm initiated a new position of $5.44 million in Cardinal Health, echoing the same consensus view of “Moderate Buy” and the average target of $266.56. While a single portfolio move of that size is not decisive on its own, it demonstrates that professional investors continue to find the risk-reward profile attractive around the current price levels. Taken together, the guidance band for fiscal 2027, the consensus valuation anchor in the mid-$260s, and ongoing institutional interest form a triangle of support for the stock, especially when combined with the evidence that the company has been able to deliver earnings above expectations in the latest quarter.

Insider transactions highlight segment challenges and confidence

The recent news flow has also featured executive share sales that shed light on internal views of Cardinal Health’s medical business. One article focusing on the head of the Global Medical Products and Distribution segment reports that this executive sold shares for proceeds of $8 million, executed at a weighted average price of $236.40 per share, with the stock finishing the following day, August 19, 2026, at $234.85. This coverage of the segment leader’s sale and outlook contextualizes the transaction by emphasizing that he continues to oversee a segment described as still being fixed, with revenue of $3.1 billion in the fourth quarter, down 2 percent year over year, and reported profit of $150 million that falls to $50 million after excluding the one-time tariff refund.

The article further notes that management expects the Global Medical Products and Distribution segment to deliver profit of $200 million to $220 million in fiscal 2027, with performance weighted to the back half of the year. That implies a planned profit level that is four times to more than four times above the adjusted $50 million figure reported for the most recent quarter, underlining how much improvement needs to occur to meet guidance. The commentary also points out that external geopolitical factors, such as a drawn-out conflict involving Iran, could push results toward the low end of the guidance range, which adds a layer of risk on top of the operational execution required in the segment.

Another insider-transaction analysis focuses on a sale by Cardinal Health’s chief information officer, who parted with 11,650 shares at a time when the stock’s closing price was $234.85 on August 19, 2026. This discussion of the CIO share sale frames the move in the broader context of the company’s share valuation and earnings momentum, suggesting that while executives have been monetizing some of their holdings, the underlying profit trajectory and analyst targets continue to support a constructive long-term narrative.

For retail investors, these executive transactions highlight an important nuance: insider sales do not mechanically signal deteriorating fundamentals, but they do warrant attention when they coincide with segments that management describes as “a work in progress.” In Cardinal Health’s case, the combination of strong consolidated earnings growth, specific operational challenges in the medical segment, and insider sales at prices in the mid-$230s provides a textured picture of both confidence and caution within the leadership team.

Stock price levels and technical context

On the market side, the latest comprehensive price snapshot in the August 23, 2026 earnings analysis places Cardinal Health at $229.48 per share, with that level sitting 11.1 percent below the 12-month high of $258.30 and significantly above the 12-month low of $145.87. The same report notes that the price is positioned in a “between range” between the extremes, which for technical observers translates into a mid-channel consolidation zone in which the stock has room to either retest its high or revert closer to the mean, depending on upcoming earnings releases and segment progress.

A separate real-time quote page indicates a current automated price reading of $230.00 for Cardinal Health, with a corresponding market capitalization of $53.38 billion as presented in that snapshot. While intraday quotes can fluctuate, the closeness of $230.00 to the $229.48 closing figure from August 23, 2026 suggests that the stock has been relatively stable across the latest trading sessions, at least in absolute dollar terms. This real-time quote overview also notes that at the current price, the stock trades slightly above its recent low for a narrow range and marginally below its short-term high, reinforcing the sense of consolidation.

For investors who follow percentage moves, the 11.1 percent discount to the 12-month high is notable because it coexists with a price gain of more than 57 percent compared with the 12-month low in the $145.87 area. That asymmetry indicates that most of the uptrend has already played out over the last year, while some additional upside potential remains if earnings and guidance continue to justify a higher valuation multiple or if analysts raise their target prices above the current consensus level of $266.56. On the downside, the strong earnings beat in the latest quarter and the guidance increase provide some cushion, but any meaningful disappointment in future quarters or a setback in the medical segment could push the stock to retest lower support levels.

Representative product: pharmaceutical distribution and medical supplies

Cardinal Health’s core business revolves around pharmaceutical distribution and medical products, with the company serving hospitals, pharmacies, and healthcare providers through large-scale logistics and supply chain management. In practice, this means Cardinal Health acts as a critical link between drug manufacturers and the sites of care, ensuring that prescription medicines, over-the-counter products, and clinical supplies reach their destinations reliably and efficiently. The company’s scale, reflected in fiscal 2026 revenue of $254.2 billion, underpins its ability to negotiate favorable terms with manufacturers while providing value-added services such as inventory management, data-driven purchasing tools, and coordinated delivery schedules.

Within the medical segment, Cardinal Health offers a range of surgical and procedural products, including gowns, gloves, drapes, and other consumables that are used every day in operating rooms and clinical settings. The Global Medical Products and Distribution segment’s $3.1 billion of fourth-quarter revenue underscores the breadth of this offering, even though that figure was down 2 percent year over year in the latest period. The profit profile, which stands at $150 million reported before adjusting for the one-time tariff refund and $50 million after that adjustment, illustrates the margin pressure that can arise in a competitive, cost-sensitive space where hospitals and health systems are focused on efficiency.

Looking ahead, the company’s guidance that the segment is expected to contribute $200 million to $220 million in profit during fiscal 2027 suggests that management is betting on operational improvements, cost controls, and possibly strategic shifts in product mix to enhance profitability. For customers, the appeal of Cardinal Health’s medical products lies in the combination of reliable supply and integrated service, which reduces administrative burden and risk of shortages. For investors, the segment is both a source of concern due to recent margin compression and a potential upside lever if planned improvements come through as expected.

Cardinal Health stock on the NYSE

Cardinal Health stock trades on the New York Stock Exchange under the ticker symbol CAH, giving US retail investors straightforward access through standard brokerage accounts. As of the close on August 23, 2026, the best-documented share price is $229.48, denominated in US dollars, and supported by multiple recent analyses that describe the same level in the context of the 12-month trading range. With a market capitalization reported at $53.38 billion in a real-time quote page and full-year fiscal 2026 revenue of $254.2 billion, the stock represents a large-cap healthcare distribution and services player whose valuation is anchored both by sizeable sales and a growing earnings base.

For investors assessing Cardinal Health, the key numerical anchors at this stage are the latest quarter’s adjusted EPS of $2.91 versus a consensus of $2.42, the fiscal 2026 revenue growth of 14 percent and net earnings growth of 10 percent, the fiscal 2027 adjusted EPS guidance band of $12.40 to $12.60, and the consensus target price of $266.56. These figures collectively frame a story in which the company is delivering on profit, aiming higher on future earnings, and trading at a price that offers double-digit percentage upside relative to the aggregated analyst view while already reflecting significant appreciation from past lows. As always, the upcoming quarters will determine whether the medical segment can move from “work in progress” to a more stable contributor, a shift that would likely be necessary to justify further re-rating of Cardinal Health stock.

Read more

Further details on Cardinal Health’s strategic priorities, investor presentations, and detailed financial statements are available on its official investor relations pages, which provide deeper insight into segment performance, capital allocation plans, and long-term targets beyond the high-level figures cited here.

Fact box

Company: Cardinal Health Inc.

ISIN: US14149Y1082

Ticker: CAH

Exchange: New York Stock Exchange (NYSE)

Price (as of August 23, 2026, market close): $229.48 USD

Market cap: $53.38 billion (as of August 24, 2026)

Sector / Industry: Health care distribution and medical products

Index membership: S&P 500